Posted by Michael Wonder on 26 Mar 2021
Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
26 March 2021 - EMA’s CHMP has adopted several important recommendations that will increase manufacturing capacity and supply of COVID-19 vaccines in the EU.
A new manufacturing site has been approved for the production of AstraZeneca’s COVID-19 vaccine active substance.
A new site has also been approved for the production of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer.
